Safety and pharmacodynamics of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration
Autor: | Nancy Chan, Lorna Rodriguez-Rodriguez, Robert Aiken, Jyoti Malhotra, Usha Malhotra, Aparna Kareddula, Joseph Aisner, Tracie Saunders, Janice M. Mehnert, Evita Sadimin, Andrew Zloza, Jenna H. Newman, Steven K. Libutti, Wafik S. El-Deiry, Melissa Frankel, Joseph R. Bertino, Joshua E. Allen, Mark N. Stein, Rohinton Tarapore, Ann W. Silk |
---|---|
Rok vydání: | 2018 |
Předmět: |
Cancer Research
business.industry Antagonist Cancer Pharmacology medicine.disease Small molecule 03 medical and health sciences 0302 clinical medicine Oncology Oral administration 030220 oncology & carcinogenesis Pharmacodynamics medicine Receptor business 030217 neurology & neurosurgery Advanced Solid Tumor |
Zdroj: | Journal of Clinical Oncology. 36:2595-2595 |
ISSN: | 1527-7755 0732-183X |
Popis: | 2595Background: ONC201 is a small molecule antagonist of DRD2, a G protein-coupled receptor overexpressed in several malignancies, that has prolonged antitumor efficacy in preclinical cancer models... |
Databáze: | OpenAIRE |
Externí odkaz: |